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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Bach1 is a transcriptional repressor of heme oxygenase 1 (HO 1,
a.k.a. HSP 32), which is an inducible enzyme and has anti oxida 
tion/anti inflammatory properties shown in various models of
organ injuries. Since oxidative stress plays a pivotal role in the
pathogenesis of nonalcoholic steatohepatitis (NASH), HO 1 induc 
tion would be expected to prevent the development of NASH. In
this study, we investigated the influence of Bach1 ablation in
mice on the progression of NASH in methionine choline deficient
(MCD) diet model. Bach1 ablation resulted in significant induction
of HO 1 mRNA and its activity in the liver. When fed MCD diet,
Bach1−/− mice exhibited negligible hepatic steatosis compared to
pronounced steatohepatitis in wild type mice with 6 fold increase
in hepatic triglyceride content. Whereas feeding of MCD diet
decreased mRNA expressions of peroxisome proliferator activated
receptor (PPAR) α and microsomal triglyceride transfer protein
(MTP) in wild type mice, there were no change in Bach1−/− mice.
In addition, hepatic concentration of malondialdehyde (MDA), a
biomarker for oxidative stress as well as plasma alanine amino 
transferase (ALT) was significantly lower in Bach1−/− mice. These
findings suggest that Bach1 ablation exerts hepatoprotective
effect against steatohepatitis presumably via HO 1 induction and
may be a potential therapeutic target.
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Introduction Nonalcoholic fatty liver disease (NAFLD) is the most major
liver dysfunction in the world and its prevalence is increasing
with epidemics of obesity, diabetes, and metabolic syndrome.
NAFLD includes wide-ranging liver disorder from simple steatosis
through steatohepatitis to cirrhosis and possibly hepatocellular
carcinoma.(1,2) About one-third of NAFLD is regarded as non-
alcoholic steatohepatitis (NASH) which shows activity of steato-
hepatitis with the potential for a lethal outcome. In the develop-
ment of NASH, “two hit theory” is assumed to be required, with
the first hit being lipid accumulation in hepatocytes increasing the
sensitivity of the liver to the second hit such as oxidative stress.(3)
In this setting, emerging animal studies have demonstrated the
protective effects of antioxidant (e.g., vitamin E, 1-aminobenzo-
triazole, curcumin, N-acetylcysteine, angiotensin II type I receptor
blockers) in experimental models of NASH.(4–7) In human, small
clinical trials have revealed potential usefulness of vitamin E in
the treatment of NASH.(8–10) Interestingly, administration of fer-
mented green tea extract which exerts antioxidant activity reduced
hepatic triglyceride content in addition to necro/inflammation and
fibrosis in rat NASH model.(11) These suggest that oxidative stress
plays a pivotal role in the pathogenesis of NASH and expected to
be one of the promising targets in the treatment of this disease.
Heme oxygenase (HO) is the rate limiting enzyme in the
catabolism of heme, to yield biliverdin, carbon monoxide (CO),
and free iron. HO exhibits antioxidant properties derived from
the elimination of prooxidant heme as well as from biological
activities of its reaction products, CO, biliverdin, bilirubin, and
iron.(12) In mammals three isoforms, designated as HO-1, HO-2
and HO-3 have been identified in the liver. Among these HO
isoforms, HO-3 is considered as processed pseudogenes derived
from HO-2 transcripts.(13) While HO-2 is constitutively expressed
mainly in parenchymal cells, HO-1 is prominent in Kupffer cells
and is markedly induced in hepatocytes in the response to various
stimuli. Interestingly, it has been reported that HO-1 expression
was significantly increased in the liver from NASH patients and
the increase reflected the severity of the disease.(14) These suggest
that HO-1 functions as a defense system against oxidative stress
in the liver. In fact, accumulating evidences have demonstrated
hepatoprotective effects of HO-1. The induction HO-1 by cobalt
protoporrphyrin (CoPP) protects human hepatocytes from ethanol-
induced cytotoxicity.(15) Ginkgo biloba extract, a naturally occur-
ring HO-1 inducer has been proved to ameliorate ethanol-induced
sustained damage and redox imbalance on rat liver.(16) In addition,
curcumin which has a beneficial effect on NASH has been
recently proved to be an HO-1 inducer.(5,17)
In addition to cytoprotective properties of HO-1, the regulatory
mechanisms of this gene have been revealed. A heme-binding
factor Bach1 functions as a transcriptional repressor of the gene
encoding HO-1 (Hmox1). Bach1 forms complexes with small Maf
proteins and competes against NF-E2 related factor (Nrf2), the
major transcriptional activator of Hmox1, for binding at the Maf
recognition elements (MAREs) of Hmox1 enhancer. Consistently,
mice lacking Bach1 exhibited constitutively high level of HO-1
expression in many tissues including the liver.(18) Further studies
of Bach1−/− mice have revealed a hepatoprotective role of Bach1
ablation in LPS-induced liver injury.(19)
In the current study, we investigated the influence of Bach1
disruption in animal NASH model. Accompanied with marked up-
regulation of HO-1 in the liver, we observed reduced hepatic
steatosis in Bach1−/− mice with altered expressions of key genes
that regulate hepatic lipid metabolism. Consistent with these
findings, the absence of Bach1 also exhibited hepatoprotection
confirmed by serum liver enzyme and hepatic malondialdehyde
(MDA) concentration. Collectively, these data suggest Bach1 as a
potential target in the treatment of NASH presumably via induc-
tion of HO-1.
Materials and Methods
Animals and experimental protocol. Male C57BL/6 mice
Ndoi: 10.3164/jcbn.09 122GFR
©2011 JCBN
162
were obtained from Charles River Laboratories (Yokohama,
Japan). The generation of Bach1−/− mice on C57BL/6 background
was described previously.(18) These mice at 10 weeks of age (5
mice per each group) were fed either methionine-choline deficient
(MCD) diet (Oriental Yeast Co., Tokyo, Japan) or standard chow
for 4 or 8 weeks with free access to drinking water. All animal
protocols and studies were performed according to the guidelines
of Institute of Laboratory Animal Science, Hiroshima University.
Histological studies. Liver samples were fixed in 10%
formalin, embedded in paraffin, and sliced into 4 μm thick. These
were subjected to standard procedure of hematoxylin and eosin
(HE) staining or Azan-Mallory staining.
Biochemical assays. Serum alanine aminotransferase (ALT)
levels were measured enzymatically. Hepatic triglyceride content
was determined using Wako E test triglyceride kit (Wako chemical,
Osaka, Japan) following lipid extraction.(20) Hepatic MDA levels
were quantified using Lipid Peroxidation Assay Kit (Calbiochem,
Gibbstown, NJ) with standardization of tissue protein concentra-
tions.
HO activity. HO activity in the liver was determined as pre-
viously described.(21,22) In brief, microsome fraction isolated by
ultracentrifugation was reacted with hemin as substrate, and
bilirubin formation was measured using Beckman DU640 spectro-
photometer (450 nm; Beckman Coulter, Fullerton, CA). The
activity was expressed as nmol bilirubin formed per hour per mg
of protein. To inhibit HO activity for a negative control, zinc
protoporphyrin (ZnPP) in phosphate buffer was injected intra-
peritoneally at a dose of 7.5 mg/kg once a week for 8 weeks.
Quantitative real time PCR. RNA was extracted from frozen
liver tissues using RNeasy Mini Kit (Qiagen, Hilden, Germany).
Complementary DNA was synthesized from 1 μg of total RNA
with GeneAmp RNA PCR Core Kit (Applied Biosystems, Foster
City, CA). Specific primers (Table 1) were designed using Primer
3 (http://frodo.wi.mit.edu/primer3/) on the basis of nucleotide
sequences from Genbank. Quantitative real-time PCR was per-
formed on Light Cycler system using Light Cycler FastStart
DNA Master Plus SYBR Green I (Roche Applied Science, Basel,
Switzerland). The mRNA expressions were normalized to the
housekeeping gene, GAPDH as an internal control.
Statistical analysis. The results are expressed as the means ±
SE. The statistical analysis was performed using Student’s t test
and differences were considered statistically significant when p
was less than 0.05.
Results
Hepatic HO 1 expression and its activity in the absence of
Bach1. Fig. 1 demonstrates the regulation of HO-1 expression
and its activity by Bach1. As shown in Fig. 1A, real-time PCR
quantified a 8-fold up-regulation of HO-1 mRNA in Bach1−/− mice
on chow diet. Despite not being statistically significant, there was
2-fold up-regulation of mRNA by MCD diet in wild type mice.
Consistent with these changes in mRNA expressions, Fig. 1B
demonstrates 5-fold increase in hepatic HO-1 activity in the
absence of Bach1, which was entirely repressed by intraperitoneal
injection of ZnPP, an HO-1 inhibitor.
Influence of Bach1 ablation on hepatic lipid metabolism.
Eight weeks feeding of MCD diet induced moderate infiltration
of inflammatory cells with macrovesicular steatosis in the liver of
wild type mice as depicted in Fig. 2A (A, B). In contrast to wild
type mice, Bach1−/− mice appeared devoid of hepatic steatosis
(C, D). In keeping with these morphological changes, hepatic
Table 1. Primer used for quantitative real time PCR
HO 1, heme oxygenase 1; PPARα, peroxisome proliferator activated receptor alpha; MTP,
microsomal triglyceride transfer protein; αSMA, alpha smooth muscle actin; TGF β, trans 
forming growth factor beta; GAPDH, glyceraldehyde 3 phosphate dehydrogenase.
Gene Forward Reverse
HO 1 acatcgacagccccaccaagttcaa ctgacgaagtgacgccatctgtgag
PPARα tgcaaacttggacttgaacg tgatgtcacagaacggcttc
MTP catgtcagccatcctgtttg ctcgcgataccacagactga
αSMA tcctccctggagaagagctac tataggtggtttcgtggatgc
TGF β tgcgcttgcagagattaaaa ctgccgtacaactccagtga
GAPDH agaacatcatccctgcatcc ttgtcattgagagcaatgcc
Fig. 1. Hepatic HO 1 expression and its activity in the absence of Bach1. (A) Wild type mice (open bar) and Bach1−/− mice (closed bar) were fed
either regular chow or MCD diet for 8 w prior to quantification of hepatic expression of HO 1 mRNA by real time PCR (n = 5/each group). (B) HO 1
activity in the liver from wild type (WT) or Bach1−/− (KO) mice were determined with standardlized of protein concentration (n = 5/each group). ZnPP
was utilized as a HO 1 inhibitor for negative control. *p<0.05, wild type vs Bach1−/− mice. J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 163
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triglyceride content increased by 6-fold in wild type mice following
MCD diet feeding whereas values remained unchanged in Bach1−/−
mice. To further explore the effect of Bach1 ablation, mRNA
expressions of key genes involving in hepatic lipid metabolism
were investigated. This revealed marked down-regulation of
PPARα and MTP in wild type mice whereas there were no signifi-
cant changes in Bach1−/− mice, suggesting that fatty acid utiliza-
tion and excretion were preserved in Bach1−/− mice on MCD diet.
Protective effect of Bach1 ablation on MCD diet induced
liver injury. Feeding of MCD diet increased serum ALT levels
in wild type mice at 4 and 8 weeks whereas it remained the basal
level in Bach1−/− mice, implying protective effect of Bach1 abla-
tion against liver injury (Fig. 3A). Consistent with these findings,
hepatic MDA concentration which reflects oxidative damage
elicited by lipid peroxidation in the liver remained unchanged in
Bach1−/− mice following MCD diet (Fig. 3B). This was in marked
Fig. 2. Influence of Bach1 ablation on hepatic lipid metabolism. (A) Liver sections from wild type (A and B) and Bach1−/− mice (C and D) fed either
regular chow (left panels) or MCD diet (right panels) were processed for haematoxylin & eosin (HE) staining. (original magnification 200×). (B)
Hepatic triglyceride concentrations in wild type (open bars) and Bach1−/− (closed bars) mice (n = 5/each group) were determined after feeding either
regular chow or MCD diet. (C) Hepatic mRNA expressions of PPARα and MTP were quantified (n = 5/each group) by quantitative real time PCR.
*p<0.05, regular chow vs MCD diet. †p<0.05, wild type vs Bach1−/− mice.doi: 10.3164/jcbn.09 122GFR
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contrast to 4-fold increase in MDA level in wild type mice on
MCD diet.
Influence of Bach1−/− ablation on hepatic fibrogenesis.
As previously reported,(23) rodents fed MCD diet develops steato-
hepatitis mimicking human NASH. Fig. 4A depicts mild peri-
cellular fibrosis with fat deposition in the liver from wild type
mice fed MCD diet (upper panel). In contrast, Bach1−/− mice dis-
played no significant change in the liver (lower panel). Consistent
with these morphological changes, hepatic mRNA expression of α
smooth muscle actin (αSMA) which is predominantly expressed
in activated stellate cells was up-regulated in the liver of wild type
mice on MCD diet while it remained unchanged in Bach1−/− mice.
Discussion
The aim of this study was to explore the influence of Bach1
ablation in the development of NASH. As demonstrated in Fig. 1,
Bach1 ablation in mice leads to significant up-regulation of HO-1
mRNA as well as its activity. This was in keeping with previous
data that hepatic expressions of HO-1 mRNA and protein were
constitutively high in the absence of Bach1.(18) To date, HO-1, β-
globin, ferritin, thioredoxin reductase1 and NADP(H) quinine
(oxido) reductase have been identified as a target genes of Bach1,
but other downstream genes of Bach1 have not been fully under-
stood.(24) HO-1 has been reported to have cytoprotective, anti-
inflammatory and anti-oxidative properties. Emerging reports
have suggested protective roles of HO-1 in experimental-induced
hepatic damage including lipopolysaccharide-induced injury,
immune liver fibrosis model, and hepatic ischemia-reperfusion
injury.(12,19,25–27) In addition, pathophysiological importance of HO-
1 has also been suggested by previous findings that HO-1 is
induced under various etiological conditions including human
NASH.(14)
The pathogenesis of NASH is widely recognized as two hit
theory, in which the first hit is an initial metabolic disturbance
causes steatosis and second pathogenic stimulus such as free
radical and cytokines triggers necro/inflammation leading to the
progression of steatohepatitis. The current study was undertaken
on the basis of our initial hypothesis that HO-1 induction by Bach1
ablation may ameliorate oxidative stress and inflammation, the
second hit in NASH pathogenesis and may repress the transition
from bland steatosis to steatohepatitis. Surprisingly, in addition
to reduction in hepatic damage, Bach1 ablation significantly
diminished hepatic steatosis following MCD feeding. This was
explained by the finding in this study that hepatic expression of
PPARα and MTP, that are involved in hepatic fatty acid oxidation
and hepatic secretion of triglyceride-rich VLDL, remained un-
changed in MCD diet-fed Bach1−/− mice in comparison to signifi-
cant reduction in wild type mice. These changes were inversely
paralleled with hepatic MDA concentrations, suggesting the possi-
bility that relief from oxidative damage in Bach1−/− mice con-
served hepatic lipid metabolism. Along a similar line, the previous
study of ob/ob mice fed MCD diet has revealed that YHK, a
naturally derived herbal medicine that is reported to reduce reac-
tive oxygen species declined hepatic steatosis via induction of
hepatic mRNAs of PPARα and MTP.(28,29) This suggests a
potential mechanism of the previous findings that antioxidant
agents have beneficial effects not only on hepatic necro/inlflam-
mation but also on hepatic steatosis.(4,28) Since mice assigned to
high fat diet or dietary choline restriction exhibited mitochondrial
dysfunction which negatively affects the bioenergenetics of liver,
antioxidative status observed in Bach−/− mice might preserve the
integrity of the mitochondria from oxidative damage and help
to maintain cellular functions including hepatic lipid metabo-
lism.(30,31) However, the current study lacks the direct evidence that
hepatoprotective property against NASH in Bach1−/− mice was due
to reduction in oxidative stress attributed to HO-1 induction, and
further investigations are needed.
As shown in Fig. 4, MCD diet caused modest pericellular
fibrosis with significant induction of αSMA mRNA in wild type
mice whereas Bach1−/− mice exhibited almost normal in liver
histology as well as αSMA expression. Reduction in hepatic
fibrosis is likely to be elicited by relief of hepatic damage and
inflammation in Bach1−/− mice. However, previous report has
demonstrated that HO-1 is expressed in human hepatic myofibro-
blast and induction of HO-1 leads to inhibition of collagen
synthesis and to reduction in proliferation of myofibroblast.(32)
This suggests direct role for HO-1 induction against the develop-
ment of hepatic fibrosis and might be a possible explanation for
our finding.
In the current study, MCD dietary model was utilized as a
NASH animal model. Although this model is widely used on the
basis that morphological changes of the liver resembles human
NASH with induction of oxidative stress, this does not entirely
reflect the etiological background of human NASH such as
obesity and insulin resistance. Alternative dietary models for
NASH include high fat diet, which develops obesity and insulin
resistance but not remarkable steatohepatitis as seen in MCD diet
model.(33) Interestingly, recent study has reported that feeding rats
with choline-deficient fat-rich diet for 8 w lead to marked steato-
hepatitis.(34)
Fig. 3. Protective effect of Bach1 ablation on MCD diet induced liver
injury. (A) Serum ALT levels were determined at indicated time points
by 8 w in wild type mice and Bach1−/− mice fed either regular chow or
MCD diet (n = 5/each group). (B) Hepatic MDA concentration was
assessed with standarlization of protein concentration in wild type
(open bar) and Bach1−/− (closed bar) mice (n = 5/each group). *p<0.05,
regular chow vs MCD diet. †p<0.05, wild type vs Bach1−/− mice. J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 165
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In conclusion, Bach1−/− mice are resistant to the development of
hepatic steatohepatitis with concomitant induction of HO-1 in
MCD diet-induced NASH model. Reduced steatosis in Bach1−/−
mice following MCD diet might be attributable to preserved
expressions of PPARα and MTP that play an important role in
hepatic fatty acid oxidation and triglyceride secretion respectively.
Hepatic levels of MDA, a biomarker of oxidative stress, as well
as serum ALT, an indicator of liver injury were significantly
decreased Bach1−/− mice compared to wild type mice, suggesting
anti-oxidative effect of HO-1 induction in the absence of Bach1.
Since oxidative stress, the second hit in NASH pathogenesis
causes impairment of cellular bioenergetics leading to further
disruption of hepatic lipid metabolism, abatement of oxidative
stress by Bach1 inhibition might be one of therapeutic strategies
for the treatment of NASH/NAFLD.
Acknowlegment
This study was supported by a Grant-in-aid from the Ministry of
Health, Labor and Welfare of Japan to S. Tazuma (Grant number:
H20-Nanchi-Ippan-025).
Abbreviations
HO heme oxygenase
NASH nonalcoholic steatohepatitis
MCD diet methionine-choline deficient diet
PPARα peroxisome proliferator-activated receptor α
MTP microsomal triglyceride transfer protein
MDA malondialdehyde
ALT alanine aminotransferase
NAFLD nonalcoholic fatty liver disease
CO carbon monoxide
Fig. 4. Influence of Bach1−/− ablation on hepatic fibrogenesis. (A) Liver sections from wild type (A and B) and Bach1−/− mice (C and D) fed either
regular chow (left panels) or MCD diet (right panels) were processed for Azan Mallory staining. (original magnification 200×). (B) Following 4 w of
either regular chow or MCD diet, hepatic mRNA expressions of αSMA were quantified (n = 5/each group) by quantitative real time PCR. *p<0.05,
regular chow vs MCD diet. †p<0.05, wild type (open bar) vs Bach1−/− mice (closed bar).doi: 10.3164/jcbn.09 122GFR
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CoPP cobalt protoporrphyrin
Nrf2 NF-E2 related factor
MAREs Maf recognition elements
HE hematoxylin and eosin
ZnPP zinc protoporphyrin
αSMA alpha smooth muscle actin
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